1 Study Coverage
1.1 Chemotheraphy-induced Nausea and Vomitting Treatment Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2021-2025) & (US$ Million) Introduction
1.2 Global Chemotheraphy-induced Nausea and Vomitting Treatment Outlook 2021 VS 2025 VS 2031
1.2.1 Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Size for the Year 2025-2031
1.2.2 Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Size for the Year 2025-2031
1.3 Chemotheraphy-induced Nausea and Vomitting Treatment Market Size, United States VS Global, 2021 VS 2025 VS 2031
1.3.1 The Market Share of United States Chemotheraphy-induced Nausea and Vomitting Treatment in Global, 2021 VS 2025 VS 2031
1.3.2 The Growth Rate of Chemotheraphy-induced Nausea and Vomitting Treatment Market Size, United States VS Global, 2021 VS 2025 VS 2031
1.4 Chemotheraphy-induced Nausea and Vomitting Treatment Market Dynamics
1.4.1 Chemotheraphy-induced Nausea and Vomitting Treatment Industry Trends
1.4.2 Chemotheraphy-induced Nausea and Vomitting Treatment Market Drivers
1.4.3 Chemotheraphy-induced Nausea and Vomitting Treatment Market Challenges
1.4.4 Chemotheraphy-induced Nausea and Vomitting Treatment Market Restraints
1.5 Study Objectives
1.6 Years Considered
2 Chemotheraphy-induced Nausea and Vomitting Treatment by Type
2.1 Chemotheraphy-induced Nausea and Vomitting Treatment Market Segment by Type
2.1.1 Aloxi (Palonosetron)
2.1.2 Kytril (Granisetron)
2.1.3 Emend (Aprepitant)
2.1.4 Others
2.2 Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type (2021, 2025 & 2031)
2.3 Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type (2025-2031)
2.4 United States Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type (2021, 2025 & 2031)
2.5 United States Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type (2025-2031)
3 Chemotheraphy-induced Nausea and Vomitting Treatment by Application
3.1 Chemotheraphy-induced Nausea and Vomitting Treatment Market Segment by Application
3.1.1 Acute Nausea and Vomitting Treatment
3.1.2 Delayed Nausea and Vomitting Treatment
3.1.3 Anticipatory Nausea and Vomitting Treatment
3.2 Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application (2021, 2025 & 2031)
3.3 Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application (2025-2031)
3.4 United States Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application (2021, 2025 & 2031)
3.5 United States Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application (2025-2031)
4 Global Chemotheraphy-induced Nausea and Vomitting Treatment Competitor Landscape by Company
4.1 Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Company
4.1.1 Top Global Chemotheraphy-induced Nausea and Vomitting Treatment Companies Ranked by Revenue (2025)
4.1.2 Global Chemotheraphy-induced Nausea and Vomitting Treatment Revenue by Player (2021-2025)
4.2 Global Chemotheraphy-induced Nausea and Vomitting Treatment Concentration Ratio (CR)
4.2.1 Chemotheraphy-induced Nausea and Vomitting Treatment Market Concentration Ratio (CR) (2021-2025)
4.2.2 Global Top 5 and Top 10 Largest Companies of Chemotheraphy-induced Nausea and Vomitting Treatment in 2021
4.2.3 Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
4.3 Global Chemotheraphy-induced Nausea and Vomitting Treatment Headquarters, Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2021-2025) & (US$ Million) Type
4.3.1 Global Chemotheraphy-induced Nausea and Vomitting Treatment Headquarters and Area Served
4.3.2 Global Chemotheraphy-induced Nausea and Vomitting Treatment Companies Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2021-2025) & (US$ Million) Type
4.3.3 Date of International Companies Enter into Chemotheraphy-induced Nausea and Vomitting Treatment Market
4.4 Companies Mergers & Acquisitions, Expansion Plans
4.5 United States Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Company
4.5.1 Top Chemotheraphy-induced Nausea and Vomitting Treatment Players in United States, Ranked by Revenue (2025)
4.5.2 United States Chemotheraphy-induced Nausea and Vomitting Treatment Revenue by Players (2023, 2024 & 2025)
5 Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Region
5.1 Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Region: 2021 VS 2025 VS 2031
5.2 Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Region (2025-2031)
5.2.1 Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Region: 2021-2025
5.2.2 Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Region (2025-2031)
6 Segment in Region Level & Country Level
6.1 North America
6.1.1 North America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size YoY Growth 2025-2031
6.1.2 North America Chemotheraphy-induced Nausea and Vomitting Treatment Market Facts & Figures by Country (2021, 2025 & 2031)
6.1.3 United States
6.1.4 Canada
6.2 Asia-Pacific
6.2.1 Asia-Pacific Chemotheraphy-induced Nausea and Vomitting Treatment Market Size YoY Growth 2025-2031
6.2.2 Asia-Pacific Chemotheraphy-induced Nausea and Vomitting Treatment Market Facts & Figures by Region (2021, 2025 & 2031)
6.2.3 China
6.2.4 Japan
6.2.5 South Korea
6.2.6 India
6.2.7 Australia
6.2.8 China Taiwan
6.2.9 Indonesia
6.2.10 Thailand
6.2.11 Malaysia
6.3 Europe
6.3.1 Europe Chemotheraphy-induced Nausea and Vomitting Treatment Market Size YoY Growth 2025-2031
6.3.2 Europe Chemotheraphy-induced Nausea and Vomitting Treatment Market Facts & Figures by Country (2021, 2025 & 2031)
6.3.3 Germany
6.3.4 France
6.3.5 U.K.
6.3.6 Italy
6.3.7 Russia
6.4 Latin America
6.4.1 Latin America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size YoY Growth 2025-2031
6.4.2 Latin America Chemotheraphy-induced Nausea and Vomitting Treatment Market Facts & Figures by Country (2021, 2025 & 2031)
6.4.3 Mexico
6.4.4 Brazil
6.4.5 Argentina
6.5 Middle East and Africa
6.5.1 Middle East and Africa Chemotheraphy-induced Nausea and Vomitting Treatment Market Size YoY Growth 2025-2031
6.5.2 Middle East and Africa Chemotheraphy-induced Nausea and Vomitting Treatment Market Facts & Figures by Country (2021, 2025 & 2031)
6.5.3 Turkey
6.5.4 Saudi Arabia
6.5.5 UAE
7 Company Profiles
7.1 GlaxoSmithKline
7.1.1 GlaxoSmithKline Company Details
7.1.2 GlaxoSmithKline Business Overview
7.1.3 GlaxoSmithKline Chemotheraphy-induced Nausea and Vomitting Treatment Introduction
7.1.4 GlaxoSmithKline Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2021-2025)
7.1.5 GlaxoSmithKline Recent Development
7.2 Helsinn
7.2.1 Helsinn Company Details
7.2.2 Helsinn Business Overview
7.2.3 Helsinn Chemotheraphy-induced Nausea and Vomitting Treatment Introduction
7.2.4 Helsinn Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2021-2025)
7.2.5 Helsinn Recent Development
7.3 Heron Therapeutics
7.3.1 Heron Therapeutics Company Details
7.3.2 Heron Therapeutics Business Overview
7.3.3 Heron Therapeutics Chemotheraphy-induced Nausea and Vomitting Treatment Introduction
7.3.4 Heron Therapeutics Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2021-2025)
7.3.5 Heron Therapeutics Recent Development
7.4 Merck & Co
7.4.1 Merck & Co Company Details
7.4.2 Merck & Co Business Overview
7.4.3 Merck & Co Chemotheraphy-induced Nausea and Vomitting Treatment Introduction
7.4.4 Merck & Co Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2021-2025)
7.4.5 Merck & Co Recent Development
7.5 Tesaro
7.5.1 Tesaro Company Details
7.5.2 Tesaro Business Overview
7.5.3 Tesaro Chemotheraphy-induced Nausea and Vomitting Treatment Introduction
7.5.4 Tesaro Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2021-2025)
7.5.5 Tesaro Recent Development
7.6 Acacia Pharma
7.6.1 Acacia Pharma Company Details
7.6.2 Acacia Pharma Business Overview
7.6.3 Acacia Pharma Chemotheraphy-induced Nausea and Vomitting Treatment Introduction
7.6.4 Acacia Pharma Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2021-2025)
7.6.5 Acacia Pharma Recent Development
7.7 Aphios
7.7.1 Aphios Company Details
7.7.2 Aphios Business Overview
7.7.3 Aphios Chemotheraphy-induced Nausea and Vomitting Treatment Introduction
7.7.4 Aphios Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2021-2025)
7.7.5 Aphios Recent Development
7.8 Barr Laboratories
7.8.1 Barr Laboratories Company Details
7.8.2 Barr Laboratories Business Overview
7.8.3 Barr Laboratories Chemotheraphy-induced Nausea and Vomitting Treatment Introduction
7.8.4 Barr Laboratories Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2021-2025)
7.8.5 Barr Laboratories Recent Development
7.9 Baxter Healthcare
7.9.1 Baxter Healthcare Company Details
7.9.2 Baxter Healthcare Business Overview
7.9.3 Baxter Healthcare Chemotheraphy-induced Nausea and Vomitting Treatment Introduction
7.9.4 Baxter Healthcare Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2021-2025)
7.9.5 Baxter Healthcare Recent Development
7.10 Eisai
7.10.1 Eisai Company Details
7.10.2 Eisai Business Overview
7.10.3 Eisai Chemotheraphy-induced Nausea and Vomitting Treatment Introduction
7.10.4 Eisai Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2021-2025)
7.10.5 Eisai Recent Development
7.11 Especificos Stendhal
7.11.1 Especificos Stendhal Company Details
7.11.2 Especificos Stendhal Business Overview
7.11.3 Especificos Stendhal Chemotheraphy-induced Nausea and Vomitting Treatment Introduction
7.11.4 Especificos Stendhal Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2021-2025)
7.11.5 Especificos Stendhal Recent Development
7.12 F.Hoffmann La Roche
7.12.1 F.Hoffmann La Roche Company Details
7.12.2 F.Hoffmann La Roche Business Overview
7.12.3 F.Hoffmann La Roche Chemotheraphy-induced Nausea and Vomitting Treatment Introduction
7.12.4 F.Hoffmann La Roche Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2021-2025)
7.12.5 F.Hoffmann La Roche Recent Development
7.13 Mundipharma
7.13.1 Mundipharma Company Details
7.13.2 Mundipharma Business Overview
7.13.3 Mundipharma Chemotheraphy-induced Nausea and Vomitting Treatment Introduction
7.13.4 Mundipharma Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2021-2025)
7.13.5 Mundipharma Recent Development
7.14 Mylan Pharmaceuticals
7.14.1 Mylan Pharmaceuticals Company Details
7.14.2 Mylan Pharmaceuticals Business Overview
7.14.3 Mylan Pharmaceuticals Chemotheraphy-induced Nausea and Vomitting Treatment Introduction
7.14.4 Mylan Pharmaceuticals Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2021-2025)
7.14.5 Mylan Pharmaceuticals Recent Development
7.15 OPKO Health
7.15.1 OPKO Health Company Details
7.15.2 OPKO Health Business Overview
7.15.3 OPKO Health Chemotheraphy-induced Nausea and Vomitting Treatment Introduction
7.15.4 OPKO Health Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2021-2025)
7.15.5 OPKO Health Recent Development
7.16 Orchid Healthcare
7.16.1 Orchid Healthcare Company Details
7.16.2 Orchid Healthcare Business Overview
7.16.3 Orchid Healthcare Chemotheraphy-induced Nausea and Vomitting Treatment Introduction
7.16.4 Orchid Healthcare Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2021-2025)
7.16.5 Orchid Healthcare Recent Development
8 Research Findings and Conclusion
9 Appendix
9.1 Research Methodology
9.1.1 Methodology/Research Approach
9.1.2 Data Source
9.2 Author Details
9.3 Disclaimer

List of Tables
Table 1. Chemotheraphy-induced Nausea and Vomitting Treatment Market Size United States VS Global, CAGR (2021 VS 2025 VS 2031)
Table 2. Chemotheraphy-induced Nausea and Vomitting Treatment Market Trends
Table 3. Chemotheraphy-induced Nausea and Vomitting Treatment Market Drivers
Table 4. Chemotheraphy-induced Nausea and Vomitting Treatment Market Challenges
Table 5. Chemotheraphy-induced Nausea and Vomitting Treatment Market Restraints
Table 6. Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type: 2021 VS 2025 VS 2031 (US$ Million)
Table 7. United States Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type: 2021 VS 2025 VS 2031 (US$ Million)
Table 8. Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application: 2021 VS 2025 VS 2031 (US$ Million)
Table 9. United States Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application: 2021 VS 2025 VS 2031 (US$ Million)
Table 10. Top Chemotheraphy-induced Nausea and Vomitting Treatment Companies in Global Market, Ranking by Revenue (2021)
Table 11. Global Chemotheraphy-induced Nausea and Vomitting Treatment Revenue by Player, (US$ Million), 2021-2025
Table 12. Global Chemotheraphy-induced Nausea and Vomitting Treatment Revenue Share by Player, 2021-2025
Table 13. Global Chemotheraphy-induced Nausea and Vomitting Treatment Companies Market Concentration Ratio (CR5 and HHI)
Table 14. Global Chemotheraphy-induced Nausea and Vomitting Treatment by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment as of 2021)
Table 15. Top Players of Chemotheraphy-induced Nausea and Vomitting Treatment in Global Market, Headquarters and Area Served
Table 16. Companies Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2021-2025) & (US$ Million) Type
Table 17. Date of International Companies Enter into Chemotheraphy-induced Nausea and Vomitting Treatment Market
Table 18. Companies Mergers & Acquisitions, Expansion Plans
Table 19. Top Chemotheraphy-induced Nausea and Vomitting Treatment Players in United States Market, Ranking by Revenue (2021)
Table 20. United States Chemotheraphy-induced Nausea and Vomitting Treatment Revenue by Players, (US$ Million), 2023, 2024 & 2025
Table 21. United States Chemotheraphy-induced Nausea and Vomitting Treatment Revenue Share by Players, 2023, 2024 & 2025
Table 22. Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Region (US$ Million): 2021 VS 2025 VS 2031
Table 23. Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Region (2021-2025) & (US$ Million)
Table 24. Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Size Forecast by Region (2025-2031) & (US$ Million)
Table 25. North America Chemotheraphy-induced Nausea and Vomitting Treatment Sales in Value by Country (2025-2031) & (US$ Million)
Table 26. Asia Pacific Chemotheraphy-induced Nausea and Vomitting Treatment Sales in Value by Region (2025-2031) & (US$ Million)
Table 27. Europe Chemotheraphy-induced Nausea and Vomitting Treatment Sales in Value by Country (2025-2031) & (US$ Million)
Table 28. Latin Americaa Chemotheraphy-induced Nausea and Vomitting Treatment Sales in Value by Country (2025-2031) & (US$ Million)
Table 29. Middle East and Africa Chemotheraphy-induced Nausea and Vomitting Treatment Sales in Value by Country (2025-2031) & (US$ Million)
Table 30. GlaxoSmithKline Company Details
Table 31. GlaxoSmithKline Business Overview
Table 32. GlaxoSmithKline Chemotheraphy-induced Nausea and Vomitting Treatment Product
Table 33. GlaxoSmithKline Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2021-2025) & (US$ Million)
Table 34. GlaxoSmithKline Recent Development
Table 35. Helsinn Company Details
Table 36. Helsinn Business Overview
Table 37. Helsinn Chemotheraphy-induced Nausea and Vomitting Treatment Product
Table 38. Helsinn Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2021-2025) & (US$ Million)
Table 39. Helsinn Recent Development
Table 40. Heron Therapeutics Company Details
Table 41. Heron Therapeutics Business Overview
Table 42. Heron Therapeutics Chemotheraphy-induced Nausea and Vomitting Treatment Product
Table 43. Heron Therapeutics Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2021-2025) & (US$ Million)
Table 44. Heron Therapeutics Recent Development
Table 45. Merck & Co Company Details
Table 46. Merck & Co Business Overview
Table 47. Merck & Co Chemotheraphy-induced Nausea and Vomitting Treatment Product
Table 48. Merck & Co Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2021-2025) & (US$ Million)
Table 49. Merck & Co Recent Development
Table 50. Tesaro Company Details
Table 51. Tesaro Business Overview
Table 52. Tesaro Chemotheraphy-induced Nausea and Vomitting Treatment Product
Table 53. Tesaro Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2021-2025) & (US$ Million)
Table 54. Tesaro Recent Development
Table 55. Acacia Pharma Company Details
Table 56. Acacia Pharma Business Overview
Table 57. Acacia Pharma Chemotheraphy-induced Nausea and Vomitting Treatment Product
Table 58. Acacia Pharma Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2021-2025) & (US$ Million)
Table 59. Acacia Pharma Recent Development
Table 60. Aphios Company Details
Table 61. Aphios Business Overview
Table 62. Aphios Chemotheraphy-induced Nausea and Vomitting Treatment Product
Table 63. Aphios Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2021-2025) & (US$ Million)
Table 64. Aphios Recent Development
Table 65. Barr Laboratories Company Details
Table 66. Barr Laboratories Business Overview
Table 67. Barr Laboratories Chemotheraphy-induced Nausea and Vomitting Treatment Product
Table 68. Barr Laboratories Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2021-2025) & (US$ Million)
Table 69. Barr Laboratories Recent Development
Table 70. Baxter Healthcare Company Details
Table 71. Baxter Healthcare Business Overview
Table 72. Baxter Healthcare Chemotheraphy-induced Nausea and Vomitting Treatment Product
Table 73. Baxter Healthcare Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2021-2025) & (US$ Million)
Table 74. Baxter Healthcare Recent Development
Table 75. Eisai Company Details
Table 76. Eisai Business Overview
Table 77. Eisai Chemotheraphy-induced Nausea and Vomitting Treatment Product
Table 78. Eisai Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2021-2025) & (US$ Million)
Table 79. Eisai Recent Development
Table 80. Especificos Stendhal Company Details
Table 81. Especificos Stendhal Business Overview
Table 82. Especificos Stendhal Chemotheraphy-induced Nausea and Vomitting Treatment Product
Table 83. Especificos Stendhal Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2021-2025) & (US$ Million)
Table 84. Especificos Stendhal Recent Development
Table 85. F.Hoffmann La Roche Company Details
Table 86. F.Hoffmann La Roche Business Overview
Table 87. F.Hoffmann La Roche Chemotheraphy-induced Nausea and Vomitting Treatment Product
Table 88. F.Hoffmann La Roche Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2021-2025) & (US$ Million)
Table 89. F.Hoffmann La Roche Recent Development
Table 90. Mundipharma Company Details
Table 91. Mundipharma Business Overview
Table 92. Mundipharma Chemotheraphy-induced Nausea and Vomitting Treatment Product
Table 93. Mundipharma Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2021-2025) & (US$ Million)
Table 94. Mundipharma Recent Development
Table 95. Mylan Pharmaceuticals Company Details
Table 96. Mylan Pharmaceuticals Business Overview
Table 97. Mylan Pharmaceuticals Chemotheraphy-induced Nausea and Vomitting Treatment Product
Table 98. Mylan Pharmaceuticals Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2021-2025) & (US$ Million)
Table 99. Mylan Pharmaceuticals Recent Development
Table 100. OPKO Health Company Details
Table 101. OPKO Health Business Overview
Table 102. OPKO Health Chemotheraphy-induced Nausea and Vomitting Treatment Product
Table 103. OPKO Health Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2021-2025) & (US$ Million)
Table 104. OPKO Health Recent Development
Table 105. Orchid Healthcare Company Details
Table 106. Orchid Healthcare Business Overview
Table 107. Orchid Healthcare Chemotheraphy-induced Nausea and Vomitting Treatment Product
Table 108. Orchid Healthcare Revenue in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2021-2025) & (US$ Million)
Table 109. Orchid Healthcare Recent Development
Table 110. Research Programs/Design for This Report
Table 111. Key Data Information from Secondary Sources
Table 112. Key Data Information from Primary Sources
List of Figures
Figure 1. Chemotheraphy-induced Nausea and Vomitting Treatment Product Picture
Figure 2. Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Size, (US$ Million), 2021 VS 2025 VS 2031
Figure 3. Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Size 2025-2031 (US$ Million)
Figure 4. United States Chemotheraphy-induced Nausea and Vomitting Treatment Market Size, (US$ Million), 2021 VS 2025 VS 2031
Figure 5. United States Chemotheraphy-induced Nausea and Vomitting Treatment Market Size 2025-2031 (US$ Million)
Figure 6. United States Chemotheraphy-induced Nausea and Vomitting Treatment Market Share in Global 2025-2031
Figure 7. Chemotheraphy-induced Nausea and Vomitting Treatment Report Years Considered
Figure 8. Product Picture of Aloxi (Palonosetron)
Figure 9. Product Picture of Kytril (Granisetron)
Figure 10. Product Picture of Emend (Aprepitant)
Figure 11. Product Picture of Others
Figure 12. Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Share by Type in 2025 & 2031
Figure 13. Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type (2025-2031) & (US$ Million)
Figure 14. Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Share by Type (2025-2031)
Figure 15. United States Chemotheraphy-induced Nausea and Vomitting Treatment Market Share by Type in 2025 & 2031
Figure 16. United States Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Type (2025-2031) & (US$ Million)
Figure 17. United States Chemotheraphy-induced Nausea and Vomitting Treatment Market Share by Type (2025-2031)
Figure 18. Product Picture of Acute Nausea and Vomitting Treatment
Figure 19. Product Picture of Delayed Nausea and Vomitting Treatment
Figure 20. Product Picture of Anticipatory Nausea and Vomitting Treatment
Figure 21. Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Share by Application in 2025 & 2031
Figure 22. Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application (2025-2031) & (US$ Million)
Figure 23. Global Chemotheraphy-induced Nausea and Vomitting Treatment Market Share by Application (2025-2031)
Figure 24. United States Chemotheraphy-induced Nausea and Vomitting Treatment Market Share by Application in 2025 & 2031
Figure 25. United States Chemotheraphy-induced Nausea and Vomitting Treatment Market Size by Application (2025-2031) & (US$ Million)
Figure 26. United States Chemotheraphy-induced Nausea and Vomitting Treatment Market Share by Application (2025-2031)
Figure 27. North America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size Growth Rate 2025-2031 (US$ Million)
Figure 28. United States Chemotheraphy-induced Nausea and Vomitting Treatment Market Size Growth Rate (2025-2031) & (US$ Million)
Figure 29. Canada Chemotheraphy-induced Nausea and Vomitting Treatment Market Size Growth Rate (2025-2031) & (US$ Million)
Figure 30. Europe Chemotheraphy-induced Nausea and Vomitting Treatment Market Size Growth Rate 2025-2031 (US$ Million)
Figure 31. Germany Chemotheraphy-induced Nausea and Vomitting Treatment Market Size Growth Rate (2025-2031) & (US$ Million)
Figure 32. France Chemotheraphy-induced Nausea and Vomitting Treatment Market Size Growth Rate (2025-2031) & (US$ Million)
Figure 33. U.K. Chemotheraphy-induced Nausea and Vomitting Treatment Market Size Growth Rate (2025-2031) & (US$ Million)
Figure 34. Italy Chemotheraphy-induced Nausea and Vomitting Treatment Market Size Growth Rate (2025-2031) & (US$ Million)
Figure 35. Russia Chemotheraphy-induced Nausea and Vomitting Treatment Market Size Growth Rate (2025-2031) & (US$ Million)
Figure 36. Asia-Pacific Chemotheraphy-induced Nausea and Vomitting Treatment Market Size Growth Rate 2025-2031 (US$ Million)
Figure 37. China Chemotheraphy-induced Nausea and Vomitting Treatment Market Size Growth Rate (2025-2031) & (US$ Million)
Figure 38. Japan Chemotheraphy-induced Nausea and Vomitting Treatment Market Size Growth Rate (2025-2031) & (US$ Million)
Figure 39. South Korea Chemotheraphy-induced Nausea and Vomitting Treatment Market Size Growth Rate (2025-2031) & (US$ Million)
Figure 40. India Chemotheraphy-induced Nausea and Vomitting Treatment Market Size Growth Rate (2025-2031) & (US$ Million)
Figure 41. Australia Chemotheraphy-induced Nausea and Vomitting Treatment Market Size Growth Rate (2025-2031) & (US$ Million)
Figure 42. China Taiwan Chemotheraphy-induced Nausea and Vomitting Treatment Market Size Growth Rate (2025-2031) & (US$ Million)
Figure 43. Indonesia Chemotheraphy-induced Nausea and Vomitting Treatment Market Size Growth Rate (2025-2031) & (US$ Million)
Figure 44. Thailand Chemotheraphy-induced Nausea and Vomitting Treatment Market Size Growth Rate (2025-2031) & (US$ Million)
Figure 45. Malaysia Chemotheraphy-induced Nausea and Vomitting Treatment Market Size Growth Rate (2025-2031) & (US$ Million)
Figure 46. Latin America Chemotheraphy-induced Nausea and Vomitting Treatment Market Size Growth Rate 2025-2031 (US$ Million)
Figure 47. Mexico Chemotheraphy-induced Nausea and Vomitting Treatment Market Size Growth Rate (2025-2031) & (US$ Million)
Figure 48. Brazil Chemotheraphy-induced Nausea and Vomitting Treatment Market Size Growth Rate (2025-2031) & (US$ Million)
Figure 49. Argentina Chemotheraphy-induced Nausea and Vomitting Treatment Market Size Growth Rate (2025-2031) & (US$ Million)
Figure 50. Middle East & Africa Chemotheraphy-induced Nausea and Vomitting Treatment Market Size Growth Rate 2025-2031 (US$ Million)
Figure 51. Turkey Chemotheraphy-induced Nausea and Vomitting Treatment Market Size Growth Rate (2025-2031) & (US$ Million)
Figure 52. Saudi Arabia Chemotheraphy-induced Nausea and Vomitting Treatment Market Size Growth Rate (2025-2031) & (US$ Million)
Figure 53. UAE Chemotheraphy-induced Nausea and Vomitting Treatment Market Size Growth Rate (2025-2031) & (US$ Million)
Figure 54. GlaxoSmithKline Revenue Growth Rate in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2021-2025)
Figure 55. Helsinn Revenue Growth Rate in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2021-2025)
Figure 56. Heron Therapeutics Revenue Growth Rate in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2021-2025)
Figure 57. Merck & Co Revenue Growth Rate in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2021-2025)
Figure 58. Tesaro Revenue Growth Rate in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2021-2025)
Figure 59. Acacia Pharma Revenue Growth Rate in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2021-2025)
Figure 60. Aphios Revenue Growth Rate in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2021-2025)
Figure 61. Barr Laboratories Revenue Growth Rate in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2021-2025)
Figure 62. Baxter Healthcare Revenue Growth Rate in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2021-2025)
Figure 63. Eisai Revenue Growth Rate in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2021-2025)
Figure 64. Especificos Stendhal Revenue Growth Rate in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2021-2025)
Figure 65. F.Hoffmann La Roche Revenue Growth Rate in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2021-2025)
Figure 66. Mundipharma Revenue Growth Rate in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2021-2025)
Figure 67. Mylan Pharmaceuticals Revenue Growth Rate in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2021-2025)
Figure 68. OPKO Health Revenue Growth Rate in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2021-2025)
Figure 69. Orchid Healthcare Revenue Growth Rate in Chemotheraphy-induced Nausea and Vomitting Treatment Business (2021-2025)
Figure 70. Bottom-up and Top-down Approaches for This Report
Figure 71. Data Triangulation
Figure 72. Key Executives Interviewed

The research methodology employed by VICResearch has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of VICResearch. VICResearch’s methodology can be divided into five stages:

Stage 1: Secondary research
The research team first works with magazines, industry trade group, and administration that operate in the research field. The information provided by our in-house documentation service helps us carrying out further research. Our team which has the experience as well as the knowledge efficiently extracts the accurate information from existing source.

Stage 2: Primary research: interviews with trade sources
After the first stage, the research team conducts large number of face-to-face or telephone interviews with the representative companies operating in the research field. The analysts attempt to obtain a chance to talk with leading players in the field as well as with small companies. The upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers are all included in the interviews. The data gathered during the interview is then carefully checked and compared with the secondary research.

Stage 3: Analysis of the gathered data
The analysis team checks and synthesizes the data gathered during the first two stages. To validate the data, a second series of interviews can be conducted.

Stage 4: Quantitative data
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by VICResearch. The data is based on the estimates obtained during stage 3.
The research team also provides appreciation and analysis of the market and the quantitative data contained in the reports. The data is consequently unique to VICResearch.

Stage 5: Quality control
Before publishing, every report goes under a rigorous checking and editing process, which is done by experience management team to ensure the reliability of the published data. Each analyst in the research team receives support and on-going training which is part of the VICResearch’s internal quality process.